Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment

Table 1 Decline in VC and %VC at week 52 in subpopulations characterized by baseline %VC and the lowest SpO₂

Item	Category 1 SpO₂	Category 2 Baseline %VC	High-dose Group		Low-dose Group		Placebo Group		P-value
			LS mean (n)	SE	LS mean (n)	SE	LS mean (n)	SE	H vs P	L vs P	H+L vs P
Change in VC	6MWT SpO₂≥90	%VC≥70	-0.072 (35)	0.033	-0.004 (16)	0.050	-0.090 (32)	0.035	0.7035	0.1595	0.2581
		%VC<70	-0.263 (9)	0.073	-0.185 (6)	0.090	-0.225 (9)	0.073	0.7181	0.7350	0.9919
	6MWT SpO₂<90	%VC≥70	-0.050 (36)	0.049	-0.016 (17)	0.071	-0.199 (36)	0.049	0.0359	0.0372	0.0131
		%VC<70	-0.148 (23)	0.051	-0.181 (15)	0.062	-0.168 (26)	0.048	0.7768	0.8735	0.9539
Change in %VC	6MWT SpO₂≥90	%VC≥70	-2.083 (35)	1.070	-0.420 (16)	1.580	-2.801 (32)	1.114	0.6438	0.2209	0.2927
		%VC<70	-9.084 (9)	2.446	-7.340 (6)	2.963	-7.167 (9)	2.449	0.5902	0.9647	0.7427
	6MWT SpO₂<90	%VC≥70	-1.737 (36)	1.569	-0.590 (17)	2.264	-6.080 (36)	1.568	0.0555	0.0493	0.0213
		%VC<70	-4.143 (23)	1.637	-5.090 (15)	2.079	-5.669 (26)	1.567	0.5037	0.8280	0.6158

ISSN: 1465-993X